AstraZeneca and Bristol Myers Squibb in talks over $400bn merger
AstraZeneca has opened discussions with Bristol Myers Squibb about a potential merger valued at $400bn. If completed, the deal would create one of the world's largest pharmaceutical companies, reshaping the industry's competitive landscape. Talks are ongoing and may not result in an agreement.